Comparing the current results to its competitors, Marizyme Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 20.74 %, recorded in the same quarter.
Marizyme Inc 's Comment on Competition and Industry Peers
The company markets DuraGraft, the first and only FDA-authorized medical product for intra-operative vascular conduit storage and flushing during coronary artery bypass graft (CABG) surgeries. DuraGraft is also the only product certified for this indication in Europe and other jurisdictions. The company is developing MAR-FG-001 fat grafting technology, which is not yet commercially available. Its growth strategies include commercializing DuraGraft and advancing MAR-FG-001 and related products.
Arch Therapeutics Inc's business model focuses on the development and commercialization of novel self-assembling peptide-based technologies for use in the healthcare industry.
Vycor Medical Inc has a business model focused on developing and commercializing innovative medical devices and technologies in the healthcare industry.
Therapeutic Solutions International Inc Share Performance
0.00%
This Quarter
Therapeutic Solutions International Inc
Profile
Therapeutic Solutions International Inc is a company that operates under a business model focused on researching, developing, and commercializing cutting-edge treatments and therapies for various medical conditions. Their approach involves identifying innovative technologies and products, conducting rigorous scientific research, and partnering with healthcare professionals and organizations to bring their solutions to the market. Through their business model, they aim to improve patient outcomes and revolutionize medical treatments across different fields.
Endonovo Therapeutics Inc is a biotechnology company focused on the development of non-invasive electroceuticals for regenerative therapies. Their business model centers around the research, development, and commercialization of their innovative technology that stimulates the body's natural healing process. With a focus on treating inflammatory conditions and diseases, Endonovo aims to provide advanced, non-pharmaceutical solutions for improved patient outcomes.
Catalent Incs business model centers around offering comprehensive development and delivery solutions to pharmaceutical, biotechnology, and consumer health companies. By providing a diverse array of services such as drug development, manufacturing, packaging, and supply chain management, they aim to expedite the market entry of innovative and life-saving products for their clients.
Sources:
Marizyme Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Marizyme Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
